GlassScriptPhysician profile
Joseph E Huffstutter
NPI 1902840788
$742,121.82
in general payments reported to CMS, 2019-2025
39 companies · $94K in 2025
The $94K reported for 2025 was more than what 98% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247K · 2020: $80K · 2021: $73K · 2022: $82K · 2023: $107K · 2024: $58K · 2025: $94K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $187K · Travel and Lodging: $29K · Consulting Fee: $26K · Food and Beverage: $16K · Education: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $187,386.00 |
| Travel and Lodging | $29,329.22 |
| Consulting Fee | $26,470.00 |
| Food and Beverage | $16,129.67 |
| Education | $213.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $243,690.09 | 2019-2024 | Taltz, Zepbound |
| Ucb, INC. | $131,308.96 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $117,408.82 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Janssen Scientific Affairs, LLC | $110,774.59 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $39,475.92 | 2019-2025 | |
| Glaxosmithkline, LLC. | $32,672.14 | 2019-2025 | Benlysta |
| Pfizer INC. | $27,458.00 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $18,394.49 | 2019-2025 | |
| Abbvie INC. | $4,195.24 | 2019-2025 | |
| Amgen INC. | $3,421.97 | 2019-2025 | Tavneos, Krystexxa, Enbrel |
| Genentech USA, INC. | $2,449.12 | 2019-2025 | Actemra |
| Eli Lilly and Company | $2,300.00 | 2020 | |
| Horizon Therapeutics Plc | $2,144.14 | 2019-2023 | Krystexxa |
| Regeneron Healthcare Solutions, INC. | $1,113.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $836.73 | 2019-2025 | Orencia |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $548.26 | 2020-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $521.45 | 2021-2025 | Saphnelo |
| Radius Health, INC. | $446.15 | 2019-2025 | Tymlos |
| Aurinia Pharma U.S., INC. | $358.65 | 2021-2025 | Lupkynis |
| Sandoz INC. | $299.23 | 2023-2025 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $297.76 | 2019-2025 | Ofev, Cyltezo |
| Pacira Therapeutics, INC. | $277.59 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $237.38 | 2019-2024 | Opsumit, Uptravi |
| Sobi, INC | $221.56 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $206.81 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $197.50 | 2019-2025 | Strensiq |
| Fresenius Kabi USA, LLC | $184.07 | 2023-2024 | Idacio |
| Celgene Corporation | $178.90 | 2019 | |
| Ani Pharmaceuticals, INC. | $153.62 | 2023 | Purified Cortrophin Gel |
| Organon LLC | $98.17 | 2023-2025 | Renflexis, Hadlima |
| Scilex Pharmaceuticals INC. | $65.21 | 2024-2025 | |
| Medtronic, INC. | $43.93 | 2024 | Kyphon Express II Kyphopak Tray |
| Teva Pharmaceuticals USA, INC. | $43.21 | 2023-2024 | Truxima, Simlandi |
| Hikma Pharmaceuticals USA | $28.67 | 2019-2023 | Mitigare |
| Gilead Sciences, INC. | $16.18 | 2020 | |
| Celltrion USA INC. | $14.72 | 2023 | Yuflyma |
| Fidia Pharma USA INC. | $14.00 | 2025 | Hymovis |
| Mallinckrodt Enterprises LLC | $13.67 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Huffstutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.